Heart transplant in “Nuevo León”. The first 33 cases

Eduardo Herrera Garza; Julio Molina Gamboa; Horacio Decanini Arcaute; Marcos Ibarra Flores; Myrella Torres García; Carlos Macías Hidalgo; Roberto González Oviedo; Felipe de Jesús de la Fuente Magallanes; Luis Ángel Elizondo Sifuentes; Miguel Ángel Villarreal Arredondo; Óscar Ortega Durán; Pedro Martínez Bermúdez; Armando García Castillo; Oralia Becerra García; Diana Martínez Rodríguez; Carmen Contreras Lara; María del Consuelo Olivares de la Cerda; Alfonso Treviño Treviño

2006, Number 2

Arch Cardiol Mex 2006; 76 (2)

Heart transplant in “Nuevo León”. The first 33 cases

Herrera GE, Molina GJ, Decanini AH, Ibarra FM, Torres GM, Macías HC, González OR, de la Fuente MFJ, Elizondo SLA, Villarreal AMA, Ortega DO, Martínez BP, García CA, Becerra GO, Martínez RD, Contreras LC, Olivares CMC, Treviño TA

Full text

How to cite this article

Language: Spanish
References: 30
Page: 151-162
PDF size: 138.69 Kb.

ABSTRACT

Heart failure is one of the most important causes of death worldwide. Heart transplant is the last effective alternative when the medical and surgical treatments have failed in patients with end stage heart failure, giving them an 80% one year survival rate. Unfortunately, during the outcome, the heart transplant patients can develop complications such as graft rejection and opportunistic infections because of the use of immunosuppressive therapy. In the present article we report the experience with 33 heart transplant patients. Our program not only has successfully transplanted patients with advanced age but, for the first time in Latin America we have transplanted patients assisted with the ambulatory Thoratec TLC II system. Even with limited resources, we have managed the same complications than other heart transplant programs, our 82% one year survival rate is similar than reports in medical literature.

REFERENCES

ROGER VI, WESTON SA, REDFIELD MM: Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344–50.
BARNARD CN: The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital. Cape Town. S Afr Med J 1967; 41: 1271-1274.
AZIZ S, BIEBER CP, REITZ BA, BIEBER MM, OYER PE, HOIT G, ET AL: Preparation and efficacy of Cyclosporin-A liposomes for prolongation of cardiac allograft survival. Transplant Proc 1981; 13(1 Pt 1): 410-411.
OSADA N, CHAITMAN BR, DONOHUE TJ, WOLFORD TL, STELKEN AM, MILLER LW: Long term cardiopulmonary exercise performance after heart transplantation. Am J Cardiol 1997; 79: 451-456.
TAYLOR DO, EDWARDS LB, MOHACSI PJ, BOUCEK MM, TRULOCK EP, KECK BM, ET AL: The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 2003; 22: 616–624.
KESLER KA, HANOSH JJ, O´DONNELL J, FAUST S, TURRENTINE MW, MAHOMED Y, ET AL: Heart transplantation in patients with Marfan´s syndrome: a survey of attitudes and results. J Heart Lung Transplant 1994; 13(5): 899-904.
BLANCHE C, BLANCHE DA, KEARNEY B, SANDHU M, CZER LS, KAMLOT A, ET AL: Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg 2001; 121(3): 434-435.
HERRERA GE, NOON GP, DURAND JB, STETSON SJ, ZYLICS S, JOHNSON L, ET AL: Trasplante cardíaco heterotópico: Experiencia de trece años en el Hospital Metodista del Colegio de Medicina de Baylor. Arch Inst Cardiol Mex 1999; 69: 526-533.
ROSE EA, GELIJNS AC, MOSKOWITZ AJ, HEITJAN DF, STEVENSON LW, DEMBITSKY W, ET AL: Long term use of a left ventricular assist device for end stage heart failure. N Engl J Med 2001; 345: 1435-1443.
FARRAR DJ, BUCK KE, COULTER JH, KUPA EJ: Portable pneumatic biventricular driver for the Thoratec ventricular assist device. ASAIO Journal 1997; 43: M631-M634.
LINDENFELD JA, MILLER GG, SHAKAR SF, ZOLTY R, LOWES BD, WOLFEL EE, ET AL: Drug therapy in the heart transplant recipient: Part I: Cardiac rejection and immunosuppressive drugs. Circulation 2004; 110(24): 3734-3740.
MICHAELS PJ, ESPEJO ML, KOBASHIGAWA J, ALEJOS JC, BURCH C, TAKEMOTO S, ET AL: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.
SLOTA M, GREEN M, FARLEY A, JANOSKY J, CARCILLO J: The role of gown and glove isolation in the reduction of nosocomial infection in children with solid organ transplantation. Critical Care Medicine 2001; 29(2): 405-412.
LENNER R, PADILLA M, TEIRSTEIN A, GASS A, SCHILERO G: Pulmonary complications in cardiac transplant recipients. Chest 2001; 120(2): 508-513.
GROSSI P, FARINA C, FIOCCHI R, DALLA GASPERINA D: Prevalence and outcome of invasive fungal infections in 1963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70(1): 112-116.
ANTRETTER H, HOFER D, KLAUS A, LARCHER C, MARGREITER J, MARGREITER R: Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention. Dtsch Med Wochenschr 2000; 125(15): 445-451.
GRADEK WQ, D´AMICO C, SMITH AL, VEGA D, BOOK WM: Routine surveillance endomyocardial biopsy continues to detect significant rejection late after heart transplantation. J Heart Lung Transplant 2001; 20(5): 497-502.
BALK AH, ZONDERVAN PE, VAN DER MEER P, VAN GELDER T, MOCHTAR B, SIMOONS ML, ET AL: Effect of adopting a new histological grading system of acute rejection after heart transplantation. Heart 1997; 78(6): 603-607.
MICHAELS PJ, ESPEJO ML, KOBASHIGAWA J, ALEJOS JC, BURCH C, TAKEMOTO S, ET AL: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.
WAGNER FM, REICHENSPURNER H, UBERFUHR P, WEISS M, FINGERLE V, REICHART B: Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant 1994; 13(5): 916-918.
KEOGH A: Long-term Benefits of Mycophenolate Mofetil after Heart Transplantation. Transplantation 2005; 79(3): S45-S46.
MIDTVEDT K, FAUCHALD P, LIEN B, HARTMANN A, ALBRECHTSEN D, BJERKELY BL, ET AL: Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 2003; 17: 69–74.
KNOOP C, ANTOINE M, VACHIERY JL, DEPRE G, ALONSOVEGA C, STRUELENS M, ET AL: Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Transplantation 1998; 66(7): 932-935.
HALLORAN PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
CASTRO P, ARRIAGADA G, MORENO M, MORAN S, BECKER P, ZALAQUETT R, ET AL: Humoral rejection in heart transplantation. Report of 2 cases. Rev Med Chil 2000; 128(11): 1245-1249.
MEISER BRUNO, REICHART BRUNO, ADAMIDIS IOANNIS, UBERFUHR PETER, KACZMAREK INGO: First experience with de novo Calcineurin-Inhibitor-Free Immunosuppression Following Cardiac Transplantation. American Journal of Transplantation 2005; 5(4): 827-831.
KEOGH A, RICHARDSON M, MEROULA B, RUYGROK P, SPRATT P, GALBRAITH, ET AL: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110(17): 2694-2700.
SOUZA GS, GARCIA-GALLONT R, MAIREN JA, VILLACA SS, GONTIJO RC, VIOTTI EA, ET AL: Sirolimus and Micophenolate Mofetil: A reliable drug combination to prevent acute rejection and to protect graft function after renal transplantation. A retrospective analysis of 1 year’s follow up in adult kidneyrecipients. Transplantation 2004; 78(2): 269-270.
STRAATMAN LP, COLES JG: Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70(3): 541-3.
KAVANAUGH T, YACOUB MH, KENEDY J, AUSTIN PC: Return to work after heart transplantation: 12 year follow up. J Heart Lung Transplant 1999; 18(9): 846-851.